Details of the Drug-Related molecule(s) Interaction Atlas

US8940736, 7 Drug Info

CHEMBL3699235; SCHEMBL15408805; BDBM142775; US8940736, 7

Cross-matching ID

PubChem CID

89919708

TTD Drug ID

DM9KSVI

General Information of Drug (ID: DM9KSVI)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase II alpha prime (CSNK2A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8940736, 6	DMXY4SP	N. A.	N. A.	Patented	[1]
US8940736, 23	DM3PU57	N. A.	N. A.	Patented	[1]
US8791257, 38	DMAEHCP	N. A.	N. A.	Patented	[2]
US8791257, 4	DMIQO8N	N. A.	N. A.	Patented	[2]
US8791257, 17	DMUPRX2	N. A.	N. A.	Patented	[2]
PMID22115617C2c	DMX5UKA	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase II alpha prime (CSNK2A2)	TTR93NU	CSK22_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
2	Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.
3	CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.